SizeOculis (OCS) is a United States Health Care company (Miscellaneous Commercial Services) with a market value of $462M, the 2755th largest of 3,117 United States companies the cockpit tracks. Shares closed at $7.49 on 6 Nov 2026.
Performance Over six months the shares fell 77.0%, against +9.6% for the median peer and -1.1% for the United States market (cap-weighted) — lowest of 8 in its peer set.
Valuation It trades at 1.70× book value against a peer median of 1.96× (3rd cheapest of 8).
Price implies The share price implies a return on equity of about 8.7%; Oculis delivers -44.2%, so the price asks more than the business earns today.
Short interest Short interest is 2.9% of the free float (15 Oct 2026).
Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).
Relative performance
Six months, rebased to 100: Oculis against the median of its 7 peers (local-currency closes).
Oculis financials
Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Performance: 6-month against 1-month return
Up and to the right = strong over both horizons. Oculis is the large dot.
Fundamentals: return on equity against price-to-book
A bank or insurer earning more on its equity usually trades at a higher multiple of book; points far above the trend are priced for more. Oculis is the large dot.
Capital: ROE delivered against the ROE the price implies
Above the diagonal = the price asks for a higher return on equity than the business earns today. Oculis is the large dot.
Oculis competitors and peer comparison
How Oculis compares with its peers
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
Oculis against its 7 peers (data as of 6 Nov 2026)
Measure
OCS
Peer median
Rank in peer set
1-month return
-13.5%
-2.6%
2nd lowest of 8
6-month return
-77.0%
+9.6%
lowest of 8
Return on equity
-44.2%
-26.1%
3rd lowest of 8
Price / book
1.70×
1.96×
3rd cheapest of 8
ROE the price implies
8.7%
17.2%
least demanding of 8
ROE delivered
-44.2%
-26.1%
3rd lowest of 8
Peer table
Peer set: Industry: the same industry and sector in any market, nearest in size
The cockpit's peer set: Evolent Health (EVH), SBC Medical (SBC), Tectonic Therapeutic (TECX), Adlai Nortye Ltd. Sponsored ADR (ANL), Evotec (EVT.DE), OmniAb (OABI), Silence Therapeutics PLC Sponsored ADR (SLN).
Is Oculis expensive compared with its peers?
On price / book it trades at 1.70× against a peer median of 1.96×, 3rd cheapest of 8 in its peer set. The share price implies a return on equity of about 8.7%; Oculis delivers -44.2%, so the price asks more than the business earns today.
How has Oculis stock performed?
Over six months to 6 Nov 2026 the shares returned -77.0% against +9.6% for the median peer; over one year -61.2%.